Sana Biotechnology (SANA) director awarded options for 90,000 shares at $2.96

Rhea-AI Filing Summary

Sana Biotechnology director Patrick Y. Yang received a new stock option grant, giving him the right to acquire 90,000 shares of common stock at an exercise price of $2.96 per share. The option vests in full on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, as long as he continues providing service to the company. Following this award, he holds 90,000 derivative securities linked to Sana common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yang Patrick Y

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 90,000 shares Exercise price: $2.96 per share Post-transaction derivative holdings: 90,000 options +2 more

5 metrics

Option grant size 90,000 shares Stock Option (Right to Buy) granted to director

Exercise price $2.96 per share Conversion or exercise price of options

Post-transaction derivative holdings 90,000 options Total shares following transaction

Option expiration June 3, 2036 Expiration date of stock option grant

Vesting trigger date June 4, 2027 (or earlier meeting) Cliff vesting on earlier of June 4, 2027 or 2027 annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, vests and becomes exercisable, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

annual meeting of stockholders financial

"immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc."

continuous service financial

"provided that the reporting person provides continuous service to Sana through such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yang Patrick Y

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Patrick Y. Yang	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Sana Biotechnology (SANA) director Patrick Y. Yang report in this Form 4?

Patrick Y. Yang reported a grant of stock options for 90,000 shares of Sana Biotechnology common stock. These options were awarded at a $2.96 exercise price and reflect compensation rather than an open-market purchase or sale of existing shares.

How many Sana Biotechnology (SANA) shares are covered by Patrick Y. Yang’s new options?

The new option grant covers 90,000 shares of Sana Biotechnology common stock. These derivatives give him the right to buy shares at a preset exercise price, subject to vesting conditions and continued service with the company through the vesting date.

What is the exercise price and expiration date of Patrick Y. Yang’s Sana (SANA) stock options?

The options have a $2.96 per share exercise price and expire on June 3, 2036. This means Yang can, once vested, choose to buy Sana common stock at $2.96 anytime before the June 3, 2036 expiration date if he wishes.

When do Patrick Y. Yang’s new Sana Biotechnology (SANA) options vest?

The options vest and become exercisable for 100% of the underlying 90,000 shares on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting, provided Yang continues serving the company through that vesting date.

Is Patrick Y. Yang buying or selling Sana Biotechnology (SANA) stock in this Form 4?

The filing reports an option grant, not a market trade. Yang acquired 90,000 stock options as compensation, giving future rights to buy shares at $2.96, rather than immediately buying or selling Sana common stock on the open market.

How many Sana Biotechnology (SANA)-linked derivative securities does Patrick Y. Yang hold after this grant?

After the reported transaction, Yang directly holds 90,000 derivative securities in the form of stock options. These represent rights to acquire an equal number of Sana Biotechnology common shares upon vesting and exercise at the predetermined $2.96 exercise price.